LIFE CENTER The Power to Age Beautifully Chaum

close
Bio Technology

Research Performance

Pipelines

In 2015 Chaum published Asia’s first clinical study of Embryonic stem cells and retinal cell therapy.
In addition, Chaum oversaw a dramatic increase in the success rate of stem cell cloning.

  • Embryonic Stem Cells Pipelines

    Retinal Pigment Epithelial Cells (MA09-hRPE)

    Stargardt's Macular Dystrophy (SMD)

    • F&D
    • Pre-Clinical
    • Phase ⅠⅡⅢ

    Age-related Macular Degeneration (AMD)

    • F&D
    • Pre-Clinical
    • Phase ⅠⅡⅢ

    Myopic Macular Degeneration (MMD)

    • F&D
    • Pre-Clinical
    • Phase ⅠⅡⅢ

    Note : Technology transfer & Partnership with US Ocata Therapeutics, Inc.

  • Adult Stem Cells or Somatic Cells
    Pipelines

    Placental Adherent Stromal Cells (PLX-PAD)

    Intermittent Claudication (IC)

    Note : Technology transfer & Partnership with Israel Pluristem Therapeutics, Inc.

    • F&D
    • Pre-Clinical
    • Phase ⅠⅡⅢ

    Umbilical Cord-derived Mescenchymal Stem Cells (CB-AC-01)

    Acute Cerebral Infarction

    • F&D
    • Pre-Clinical
    • Phase ⅠⅡⅢ

    Disk Degeneration

    • F&D
    • Pre-Clinical
    • Phase ⅠⅡⅢ

    Placenta-derived Mescenchymal Stem Cells (CB-AC-02)

    Alzheimer's Disease

    • F&D
    • Pre-Clinical
    • Phase ⅠⅡⅢ

    Global Cerebral Ischemia

    Note : Investigator Initiated Trial

    • F&D
    • Pre-Clinical
    • Phase ⅠⅡⅢ

    Traumatic Optic Nerve

    Note : Investigator Initiated Trial

    • F&D
    • Pre-Clinical
    • Phase ⅠⅡⅢ

    Adipose-derived Mescenchymal Stem Cells (CB-AC-03)

    Articular Cartilage Injury

    Note : Investigator Initiated Trial

    • F&D
    • Pre-Clinical
    • Phase ⅠⅡⅢ

    Disk Degeneration

    Note : Investigator Initiated Trial

    • F&D
    • Pre-Clinical
    • Phase ⅠⅡⅢ

    Rheumatoid Arthritis

    • F&D
    • Pre-Clinical
    • Phase ⅠⅡⅢ

    Diabetes mellitus

    • F&D
    • Pre-Clinical
    • Phase ⅠⅡⅢ

    Neural Progenitor Cells

    Parkinson's Disease

    Note : Investigator Initiated Trial

    • F&D
    • Pre-Clinical
    • Phase ⅠⅡⅢ

    Immunocytes

    Recurrent Glioblastoma

    Note : Investigator Initiated Trial

    • F&D
    • Pre-Clinical
    • Phase ⅠⅡⅢ

    ovarian cancer

    Note : Investigator Initiated Trial

    • F&D
    • Pre-Clinical
    • Phase ⅠⅡⅢ

    liver cancer

    Note : Investigator Initiated Trial

    • F&D
    • Pre-Clinical
    • Phase ⅠⅡⅢ

    Dendritic Cells

    • F&D
    • Pre-Clinical
    • Phase ⅠⅡⅢ
Patents

Embryonic-derived stem cell

Apply embryonic-derived stem cells for various indications by differentiating them to retinal pigment epithelium (RPE) Differentiation to various stem cells including embryonic-derived stem cells, culturing methods, and pharmaceutical composite materials.

Placenta-derived stem cell

Separation, culture, and pharmaceutical usage of placenta-derived mesenchymal stem cells for various indications.

Umbilical cord-derived stem cell

Separation, culture, and pharmaceutical usage of umbilical cord-derived stem cells for various indications.

Cord blood

Agents including cord blood or cord blood-derived stem cells and its pharmaceutical usage for various indications.

Fat-derived stem cell

Separation, culture, and pharmaceutical usage of fat-derived stem cells for various indications.

Testis-derived stem cell

Testis-derived pluripotent stem cell manufacturing methods and its pharmaceutical usage for various indications

Induced pluripotent stem cell (iPSC)

Induced pluripotent stem cell methods, associated pharmaceutical composite materials, and screening methods

Immunocyte

Natural killer cell, dendritic cell, or T lymphocyte manufacturing methods and its pharmaceutical usage for various indications including cancer

Stem cell bank

The stem cell bank operation system and its usage

platform technology

Drug screening using stem cells, customized diet suggestion system, and screening system for embryonic stem cell culture

Cosmetics

Culture fluid originated from various tissues or cells, such as placenta-derived or stem cell-derived ingredients, and cosmetics composite materials including active ingredients

Cell extract

Centrifugation bags, separation devices, etc. for extracting SVF (Stromal Vascular Fraction) or stem cells

Papers
Clinical
SVF Procedure

Adipose Stem Cells

Adipose stem cells are ideal for regenerative medicine due to the large amount that liposuction can easily obtain from a relatively small amount of adipose tissue.

Up until now Adipose stem cells have primarily been used for wrinkle improvement and cosmetic surgeries. However recent research has found that Adipose stem cells contain a high amount of mesenchymal stem cells, which can be used in cell restoration. Adipose stem cells are now being used to treat various diseases such as myocardial infarction, diabetes, liver ailments, ischemic peripheral circulatory disorders, and urinary incontinence.

Definition of SVF Therapy

Adipose tissues are major sources of stem cells. SVF (Stromal Vascular Fraction) is defined as a therapy in which stem cells are injected intravenously. The stem cells (2 to 5x106 units) are safely harvested from adipose tissues obtained via liposuction on the abdominal region.

Effects of SVF Therapy

The mainpurpose of SVF therapy is the regeneration of stem cells. Additionally, it is effective in treating chronic fatigue and preventing aging as it helps to aid in the formation of growth factors and anti-inflammatory factors. Furthermore, there have been many patients who reported improved eyesight, male performance, and hair growth.

SVF Programs

Facial Injection Improve skin elasticity through the formation of new blood vessels and fresh collagens. Intra-Venous Injection Achieve an Anti-Aging effect by treating the clinical symptoms related to aging. Joint Cartilage Injection Reduce joint inflammation and pain through the regeneration of articular cartilage.

Cord Blood Clinical Trial

Cord blood stem cells are used therapeutically in transplants to help cure, treat and repair damaged blood and immune systems. Cord blood stem cells are being studied for potential use in regenerative medicine.

CHA has been applying the stem cells to Cerebral Palsy patients since 2009 and developing pipeline for Stroke and Alzheimer's. Chaum provides opportunity to participate in the clinical trial for Cord Blood.

We expect that this will help stimulate and guide the body's own repair system to heal damaged tissue and organs without any side effects.

Benefits of Cord Blood Clinical Trial

  • Cord Blood has abundant growth factors.
  • Cord Blood has excellent capabilities of differentiation.
  • It's clearly proven that there is no adverse effect of transplanting cord blood.
  • CHA Health Systems Group's Cord Blood Bank has total 900 transplanting cases).
  • Cord Blood Stem Cell Collection &
    Transplant Process
  • Cord blood transplant clinical status

    It is ongoing to "Randomized, double-blind, placebo-controlled and pre-clinical studies for the potential efficacy and safety about improving clinical aging indicators by injection of Umbilical cord blood or plasma to adults in previous step of decrepitude" approved by the IRB.
    Approximately 53% of the participants 84 (including during clinical studies with placebo) until now seemed to improve in the next part.

Top